Pioneering
CD30 Targeting
in Cell Therapy

Late stage clinical program with
RMAT and PRIME Designation

Differentiated
Allogeneic Platform

Based on Virus specific T cells
and CD30 CAR

Experienced
Leadership Team

Building in-house
Manufacturing Facility

Press Releases & Events